Nithya

Pharma and healthcare Analyst at Sanford Bernstein. Views expressed on Twitter are personal

[Nithya @NithyaBala84]

@salilkallianpur 1. Leverage technology and get otherwise creative in addressing the demand in smaller towns and rural India 2. Invest in research/innovation 3. Government has to pay for innovation through higher spending and universal coverage.

[CNBC-TV18 @CNBCTV18News]

The US has said that it supports waiving intellectual property protections for #COVID vaccines. @_prashantnair & @Reematendulkar speak to @NithyaBala84 of Sanford Bernstein. She says that the potential IP waiver is good news and that DRL is likely to benefit the most. (1/2)

[ET NOW @ETNOWlive]

#TheMarket | Beyond #Remdesivir, what is in the #COVID portfolio of top pharma companies? Nithya Balasubramanian of Sanford Bernstein gives the details

@NithyaBala84 #pharma #COVIDSecondWave

[Nithya @NithyaBala84]

Bernstein India Healthcare Analyst on Worsening Covid-19 Situation in India - Bloomberg https://t.co/3gdgCLHLit

[CNBC-TV18 @CNBCTV18News]

SEC likely to give a decision on Emergency Approval to Sputnik V vaccine. @NithyaBala84, Director, Sanford Bernstein says the approval will be a positive for Dr Reddy's Lab. Tells @ekta_batra @latha_venkatesh that Sun Pharma & Cipla are among their top recommendations

[CNBC-TV18 @CNBCTV18News]

In conversation with @NithyaBala84, Director, Sanford Bernstein, @SurabhiUpadhyay @latha_venkatesh @_anujsinghal discuss their top picks from the pharma space. They have an Outperform rating on Cipla & Sun Pharma and are the top picks from the sector, she says

[CNBC-TV18 @CNBCTV18News]

#SunPharma & 7 executives have settled the case related to Aditya Medisales with SEBI. @ekta_batra discusses how this will impact the company, in conversation with Sanford Bernstein’s @NithyaBala84.

[Nithya @NithyaBala84]

My thoughts on the PLI scheme in Pharma @CNBCTV18News

[CNBC-TV18 @CNBCTV18News]

#OnCNBCTV18 | The Govt approves the applications of #AurobindoPharma & @kapl_bangalore under the #PLI scheme. @latha_venkatesh​ & @_soniashenoy discuss the prospects for the cos, the industry with Sudarshan Jain of @IPAOfficialPage & Nithya Balasubramanian of Sanford Bernstein​.

[Nithya @NithyaBala84]

My views on the vaccine rollout. ��@BloombergTV⁩ India Starts Massive Covid-19 Vaccine Drive - Bloomberg https://t.co/pX7n5l8u5q

[Salil @salilkallianpur]

Healthcare NGO raises concerns over Covaxin https://t.co/p65epr4Vy4

[CNBC-TV18 @CNBCTV18News]

#3QWithCNBCTV18 | Discussing the expectations for Q3 pharma earnings, Nithya Balasubramanian, Director, Sanford Bernstein tells @latha_venkatesh & @_soniashenoy​ that she will watch out for sales and marketing expenses for pharma companies this quarter

[Nithya @NithyaBala84]

My views on the vaccine race in India and the sector ⁦@markets⁩ https://t.co/K3OzYzoifW

[ET NOW @ETNOWlive]

Watch the full interview with @NithyaBala84, Sanford Bernstein here!
.
.
https://t.co/ItHOiQ9iiZ
.
.
@AB_insights

[Nithya @NithyaBala84]

Will a small, long-shot U.S. company end up producing the best coronavirus vaccine? | Science | AAAS https://t.co/ewCXqtfpWW

[The Ken @TheKenWeb]

[Free Story]

India needs to vaccinate at least 60% of its population to attain herd immunity. But its health minister and vaccine regulator don’t see eye-to-eye, and there’s little information on who will fund the Phase III trials.

https://t.co/hhrx7HycC3

[Nithya @NithyaBala84]

Happy to see that my report on vaccines is triggering more conversations. Another fantastic piece by @dawalelo for @TheKenWeb.

[Maitri Porecha @dawalelo]

Last Friday, in AIIMS, New Delhi, up to 50 persons involved in Covaxin #COVID19 vaccine candidate trial were given Dose 2 of vaccine in Phase two clinical trials. @TheKenWeb hit the ground and managed to speak to a few of them. #Thread - https://t.co/maaLs3TEho Sign up. Free Read

[CNBC-TV18 @CNBCTV18News]

#OnCNBCTV18 | As the earnings season begins, Director at Sanford Bernstein, @NithyaBala84 shares her views on Pharma Q2FY21 expectations, in conversation with @latha_venkatesh and @_soniashenoy

[Nithya @NithyaBala84]

A very well written note on the COVID vaccine challenges by ⁦@AnooBhu⁩ for ⁦@IndiaSpend⁩. Happy that my report was of help.⁩ India's COVID-19 Dilemma: Adults Need Vaccines, Supply Chains Geared For Children https://t.co/zFGNhtDriN

[Nithya @NithyaBala84]

Congratulations @shrishail_ @diliprathore09 @kaustubh124

[ET Brand Equity @ETBrandEquity]

Congratulations on adding another feather to your cap
@ibreathefree, @schbang. Well deserved victory at #ETSharkAwards'20.

[Nithya @NithyaBala84]

My thoughts on the recent Pharma rally. Thanks @CNBCTV18Live and @latha_venkatesh for having me. #pharma #Nifty #cipla #lupin

[CNBC-TV18 @CNBCTV18Live]

#CNBCTV18Market | Sanford Bernstein's #pharma analyst Nithya Balasubramanian feels Perrigo’s recall of Albuterol inhalers could be a bigger opportunity for Lupin than Cipla